HOUSTON & LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, today announced that Kevin Hrusovsky, Quanterix Chief Executive Officer (CEO) and outspoken advocate for transforming healthcare into personalized precision health and medicine, will participate in the 2017 Super Bowl Brain Health Summit on Saturday, February 4. The annual gathering of experts and thought leaders in brain health has been organized by the Global Brain Health Coalition (GBHC) and the Brain Treatment Foundation to discuss the current state and future of military and veteran brain health.
“Concussions and traumatic brain injuries are not just an issue for athletes, but also for our veterans and active military. We applaud the leadership displayed by the National Football League (NFL) and General Electric (GE) to make the Head Health Initiative a successful effort to improve the safety of athletes, members of the military and society overall,” said Hrusovsky. “This weekend, we look forward to continuing our work in support of athletes and military around the world along with experts in the field of brain health to advance neurodegenerative biomarker research. Our objective is to help athletes safely participate in their sport, and our military to successfully manage traumatic brain injuries suffered on the battlefield.”
Quanterix, which is a two-time winner of the GE - NFL Head Health Challenge, has developed Simoa, the digital ELISA technology that can count single protein molecules. Simoa has also been shown in over 30 peer reviewed scientific publications to have the capability to detect biomarkers of mild to severe traumatic brain injury in blood. Quanterix now offers more than 10 different detection test kits used in research for detecting neurological disorders and traumatic brain injuries in blood.
As reported recently, researchers have begun using Quanterix’ technology to search for early signs of brain injury in blood and are racing for a way to diagnose Chronic Traumatic Encephalopathy (CTE) and other neurodegenerative diseases in the living. Recent advances were published last month in a study by researchers at the National Institutes of Health (NIH), who found that the blood protein tau could be an important new clinical biomarker for better identifying athletes who need more recovery time before safely returning to play after a sports-related concussion. The study appears in the January 6, 2017 issue of Neurology, the medical journal of the American Academy of Neurology.
Simoa, which has been validated and reported by more than 80 peer-reviewed publications, gives researchers a way to closely examine critical biomarkers in a majority of disease areas, including oncology, neurology, cardiology, infectious disease and inflammation. Quanterix enables the development of methods that provide much earlier disease detection, better prognoses and enhanced treatment methods.
About Quanterix
Quanterix is a company that’s digitizing biomarker analysis to advance the science of precision health. The company’s digital health solution, Simoa, is changing the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. In doing so, Quanterix enables much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of disease areas, including oncology, neurology, cardiology, inflammation and infectious disease. Click here to view the 35th Annual J.P. Morgan Healthcare Conference Presentation: “The Next Frontier of Medicine” highlighting company strategy, milestones and objectives. The company was established in 2007 and is located in Lexington, Massachusetts.
